MabVax Therapeutics, Telik to merge

Wednesday, May 14, 2014

MabVax Therapeutics, a privately held cancer immunotherapy company, and Telik, a clinical stage oncology drug development company, have agreed to merge. MabVax and Telik will be combined into a publicly traded company focused on the development of proprietary immunotherapy-based products to diagnose and treat cancer. 

[Read More]